Holen Sie sich die Stockscreener-App
2.51
0.28%
-0.007
Schlusskurs vom Vortag:
$2.517
Offen:
$2.55
24-Stunden-Volumen:
30,640
Relative Volume:
0.21
Marktkapitalisierung:
$76.89M
Einnahmen:
$6.21M
Nettoeinkommen (Verlust:
$-19.92M
KGV:
-2.3905
EPS:
-1.05
Netto-Cashflow:
$-16.76M
1W Leistung:
+9.13%
1M Leistung:
+2.03%
6M Leistung:
-9.06%
1J Leistung:
+4.05%
1-Tages-Spanne:
$2.47
$2.58
1-Wochen-Bereich:
$2.2709
$2.58
52-Wochen-Spanne:
$1.99
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
Firmenname
InspireMD Inc.
Sektor
Branche
Telefon
972 3 6917691
Adresse
4 Menorat Hamaor Street, Tel Aviv
Vergleichen Sie NSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.51 | 70.46M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2016-01-07 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2013-11-26 | Eingeleitet | Oppenheimer | Outperform |
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
Is InspireMD Inc. a good long term investmentConsistent triple returns - jammulinksnews.com
What drives InspireMD Inc. stock priceConsistent wealth multiplication - jammulinksnews.com
How InspireMD Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser
InspireMD to Announce Second Quarter 2025 Financial Results - The Manila Times
InspireMD, Inc. Schedules Release of Second Quarter 2025 Financial Results and Conference Call - Quiver Quantitative
InspireMD Inc. Stock Analysis and ForecastAccelerated capital growth - jammulinksnews.com
What analysts say about InspireMD Inc. stockFree Investment Portfolio Suggestions - Autocar Professional
Brown Advisory Inc. Takes $27,000 Position in InspireMD, Inc. (NYSE:NSPR) - Defense World
InspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid Stent - MSN
InspireMD Launches CGuard Prime Carotid Stent System in the U.S. - MSN
What makes InspireMD Inc. stock price move sharplyInvestor Favorite Picks - Newser
Why InspireMD Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
InspireMD Launches CGuard Prime Stent in U.S. Market - The Globe and Mail
InspireMD launches CGuard Prime carotid stent in US after FDA approval By Investing.com - Investing.com South Africa
InspireMD Launches Carotid Stent System for the Preventing Strokes - Diagnostic and Interventional Cardiology
InspireMD stock rises after US commercial launch of carotid stent system - Investing.com Nigeria
InspireMD stock rises after US commercial launch of carotid stent system By Investing.com - Investing.com South Africa
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke - The Manila Times
InspireMD launches CGuard Prime carotid stent in US after FDA approval - Investing.com
NSPR launches CGuard Prime in U.S.; 8-K filed with Exhibit 99.1 | NSPR SEC FilingForm 8-K - Stock Titan
InspireMD, Inc.(NasdaqCM: NSPR) added to Russell 3000E Index - MarketScreener
InspireMD, Inc.(NasdaqCM: NSPR) added to Russell 3000E Value Index - MarketScreener
Why Did InspireMD Plunge 10.71% Despite FDA Approval? - AInvest
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - GlobeNewswire
InspireMD Gains FDA Approval for CGuard Stent System - TipRanks
InspireMD’s embolic prevention system gains CE Mark approval - Yahoo Finance
InspireMD receives CE mark approval for CGuard Prime stent system By Investing.com - Investing.com South Africa
InspireMD Gains CE Mark for Stroke Device CGuard Prime - MarketScreener
InspireMD Gains CE Mark Approval for CGuard® Prime - TipRanks
InspireMD announces CE Mark approval for CGuard Prime EPS - TipRanks
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - The Manila Times
InspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent System - Nasdaq
InspireMD Announces CE Mark Approval for CGuard® Prime - GlobeNewswire
Finanzdaten der InspireMD Inc.-Aktie (NSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):